As filed with the Securities and Exchange Commission on January 22, 2014
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ACCELERON PHARMA INC.
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of incorporation or organization) |
2836 (Primary Standard Industrial Classification Code Number) |
27-0072226 (I.R.S. Employer Identification Number) |
128 Sidney Street
Cambridge, MA 02139
(617) 649-9200
(Address, including zip code, and telephone number, including
area code, of registrant's principal executive offices)
John L. Knopf, Ph.D.
Chief Executive Officer and President
128 Sidney Street
Cambridge, MA 02139
(617) 649-9200
(Name, address, including zip code, and telephone number, including
area code, of agent for service)
Copies to: | ||||
Marc Rubenstein, Esq. Ropes & Gray LLP Prudential Tower 800 Boylston Street Boston, MA 02199 (617) 951-7000 |
John D. Quisel, Ph.D., Esq. Vice President, General Counsel and Secretary Acceleron Pharma Inc. 128 Sidney Street Cambridge, MA 02139 (617) 649-9200 |
Jonathan L. Kravetz, Esq. Brian P. Keane, Esq. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. One Financial Center Boston, MA 02111 (617) 542-6000 |
Approximate date of commencement of proposed sale to public:
As soon as practicable after this Registration Statement is declared effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. o
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ý 333-193252
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer o | Accelerated filer o | Non-accelerated filer ý (Do not check if a smaller reporting company) |
Smaller reporting company o |
CALCULATION OF REGISTRATION FEE
|
||||||||
Title of each class of securities to be registered |
Amount to be registered(1) |
Proposed maximum aggregate offering price per share |
Proposed maximum aggregate offering price |
Amount of registration fee(2) |
||||
---|---|---|---|---|---|---|---|---|
Common Stock, $0.001 par value |
460,000 | $50.00 | $23,000,000 | $2,963 | ||||
|
The Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.
Explanatory note and incorporation by reference
This Registration Statement is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "Securities Act"). The contents of the Registration Statement on Form S-1 (File No. 333-193252) filed by Acceleron Pharma Inc. with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act, which was declared effective by the Commission on January 22, 2014, are incorporated by reference into this Registration Statement.
The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts, on January 22, 2014.
ACCELERON PHARMA INC. | ||||
By: |
/s/ JOHN KNOPF, PH.D. John L. Knopf, Ph.D. Chief Executive Officer and President |
Signatures
Pursuant to the requirements of the Securities Act, this Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.
Signature
|
Title
|
Date
|
||
---|---|---|---|---|
/s/ JOHN KNOPF, PH.D. John L. Knopf, Ph.D. |
Chief Executive Officer and President (Principal Executive Officer) | January 22, 2014 | ||
* Kevin F. McLaughlin |
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
January 22, 2014 |
||
* Anthony B. Evnin, Ph.D. |
Director |
January 22, 2014 |
||
* Jean M. George |
Director |
January 22, 2014 |
||
* George Golumbeski, Ph.D. |
Director |
January 22, 2014 |
Signature
|
Title
|
Date
|
||
---|---|---|---|---|
* Edwin M. Kania, Jr. |
Director | January 22, 2014 | ||
* Tom Maniatis, Ph.D. |
Director |
January 22, 2014 |
||
* Terrance G. McGuire |
Director |
January 22, 2014 |
||
* Richard F. Pops |
Director |
January 22, 2014 |
||
* Joseph S. Zakrzewski |
Director |
January 22, 2014 |
*by: | /s/ JOHN KNOPF, PH.D. Attorney-in-Fact |
Exhibit Number
|
Description of Exhibit | ||
---|---|---|---|
5.1 | Opinion of Ropes & Gray LLP | ||
23.1 |
Consent of Ernst & Young LLP |
||
23.2 |
Consent of Ropes & Gray LLP (included in Exhibit 5.1) |
||
24.1 |
* |
Power of Attorney |